Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.

Prostate-specific membrane antigen (PSMA) is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer (PC), making it an optimal target for the treatment of metastasized PC.

Radioligand therapy (RLT) with 177Lu-PSMA-DKFZ-617 (Lu-PSMA) is a targeted therapy for metastatic PC. In this study, we retrospectively analyzed the side effects and the response rate of 24 hormone and/or chemorefractory PC patients with a mean age of 75. 2 years (range: 64-82) with distant metastases and progressive disease according to the PSA level, who were treated with Lu-PSMA. Median PSA was 522 ng/ml (range: 17-2360). Forty-six cycles of Lu-PSMA were performed. Of the 24 patients, 22 received two cycles. Eight weeks after the first cycle of Lu-PSMA therapy 79. 1% experienced a decline in PSA level. Eight weeks after the second cycle of Lu-PSMA therapy 68. 2% experienced a decline in PSA relative to the baseline value. Apart from two cases of grade 3 anemia, there was no relevant hemato- or nephrotoxicity (grade 3 or 4). These results confirmed that Lu-PSMA is a safe treatment option for metastatic PC patients and has a low toxicity profile. A positive response to therapy in terms of decline in PSA occurs in about 70% of patients.

Oncotarget. 2016 Feb 08 [Epub ahead of print]

Hojjat Ahmadzadehfar, Elisabeth Eppard, Stefan Kürpig, Rolf Fimmers, Anna Yordanova, Carl Diedrich Schlenkhoff, Florian Gärtner, Sebastian Rogenhofer, Markus Essler

Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. , Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. , Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. , Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany. , Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. , Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. , Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany. , Department of Urology, University Hospital Bonn, Bonn, Germany. , Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe